Aptose Biosciences (TSE:APS) Reaches New 1-Year Low – Should You Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) hit a new 52-week low during trading on Tuesday . The stock traded as low as C$1.98 and last traded at C$2.50, with a volume of 27932 shares traded. The stock had previously closed at C$4.56.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners upgraded shares of Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th.

Aptose Biosciences Stock Performance

The firm has a market cap of C$105.92 million, a PE ratio of -0.49 and a beta of 1.36. The company has a debt-to-equity ratio of -117.37, a current ratio of 1.05 and a quick ratio of 5.41. The company has a 50 day simple moving average of C$6.52 and a 200-day simple moving average of C$10.45.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.